Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

ALPRAZOLAM AND DEPRESSION - A REVIEW OF RISKS AND BENEFITS Symposium on Issues in the Clinical Use of Alprazolam Kravitz, H. M., Fawcett, J., Newman, A. J., Schatzberg, Ballenger, J. C., WEISSMAN PHYSICIANS POSTGRADUATE PRESS. 1993: 78–85

Abstract

Therapeutic efficacy for depression and panic disorder has been demonstrated with the triazolobenzodiazepine alprazolam. However, potentially serious adverse events, including depression and suicide attempts, have been reported in patients taking this medication. In this paper, reports addressing the association between each of these two events and benzodiazepine use in general and, more specifically, alprazolam use, are reviewed. We conclude that while these adverse events do occur in patients taking alprazolam, the causal relationship remains unclear and requires further study. Fortunately, these events are observed only rarely, so the prudent clinician may continue to safely prescribe this useful medication.

View details for Web of Science ID A1993MQ07200007

View details for PubMedID 8262892